FDA Clearance Tracker · P970043-S022
LADARVISION 4000 EXCIMER LASER SYSTEM AND THE LADAR 6000 EXCIMER LASER SYSTEM
Last checked: Nov 20, 2026Latest source record: May 2, 2006 (this decision)Source: openFDAMethods & limitations
Decided
May 2, 2006
Approved
Time to decision
180 days
Received Nov 3, 2005. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P970043-S022
- Device name
- LADARVISION 4000 EXCIMER LASER SYSTEM AND THE LADAR 6000 EXCIMER LASER SYSTEM
- Applicant
- Alcon Laboratories
- Applicant location
- Fort Worth, TX
- Received
- Nov 3, 2005
- Decided
- May 2, 2006
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P970043
Device type
- Device type
- Excimer laser system (LZS)
- Device class
- Class III
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE LADARVISION 4000 EXCIMER LASER SYSTEM AND THE LADAR 6000 EXCIMER LASER SYSTEM. THESE DEVICES USE A 6.5 MM OPTICAL ZONE AND A 9.0 TREATMENT ZONE AND ARE INDICATED FOR WAVE-FRONT GUIDED CUSTOMCORNEA LASER ASSISTED IN-SITU KERATOMILEUSIS (LASIK): 1) FOR THE REDUCTION OR ELIMINATION OF MIXED ASTIGMATISM 1.00 D TO LESS THAN 5.00 D CYCLOPLEGIC CYLINDER MAGNITUDE AT THE SPECTACLE PLANE, WHICH IS GREATER THAN THE SPHERE MAGNITUDE, AND THE CYLINDER AND SPHERE HAVE OPPOSITE SIGNS; 2) IN PATIENTS 21 YEARS OF AGE OR OLDER; AND 3) IN PATIENTS WITH DOCUMENTED STABILITY OF REFRACTION FOR THE PRIOR 12 MONTHS, AS DEMONSTRATED BY A CHANGE IN SPHERE AND CYLINDER OF LESS THAN OR EQUAL TO 0.50 D.
Source documents
Other decisions for Alcon Laboratories
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K254052 · Decided Feb 13, 2026 · 58 days after receipt
Device type: Lenses, Soft Contact, Daily Wear (LPL) · Ophthalmology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.